drugset / Trial / NCT03915964
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
RandomizedParallel-groupOpen-labelTreatment
Summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
Timeline
- Start
- 2019-04-25
- Primary completion
- 2025-05-28
- Completion
- 2025-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Comparator | Etanercept | Protein / enzyme biologic | — | Subcutaneous |